# Microbiology Devices; Reclassification of Certain Hepatitis C Virus Antibody Assay Devices, Renamed to Hepatitis C Virus Antibody Tests
> **Food and Drug Administration** · Final amendment; final order. · Published 2021-11-22 · Effective 2021-12-22 · 86 FR 66173
## Document
- **Document number:** 2021-25374
- **Category:** fda-device
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 86 FR 66173
- **CFR reference:** 21 CFR 866
- **Publication date:** 2021-11-22
- **Effective date:** 2021-12-22
- **HHS docket:** Docket No. FDA-2020-N-1082
## Abstract

The Food and Drug Administration (FDA or the Agency) is issuing a final order to reclassify certain hepatitis C virus (HCV) antibody assay devices intended for the qualitative detection of HCV, postamendments class III devices (product code MZO) into class II (general controls and special controls), subject to premarket notification. FDA is renaming and codifying these devices under the classification regulation named "hepatitis C virus (HCV) antibody tests." FDA is also identifying the special controls that the Agency believes are necessary to provide a reasonable assurance of safety and effectiveness of these devices.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2021/11/22/2021-25374/microbiology-devices-reclassification-of-certain-hepatitis-c-virus-antibody-assay-devices-renamed-to)
---
*AI Analytics · CC0 1.0*